Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
| ▸ | MME | P08473 | 7/20 | 0.54 |
| ▸ | ACE | P12821 | 6/20 | 0.54 |
| ▸ | CPA1 | P15085 | 2/20 | 0.54 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | CDC25B | P30305 | 1/20 | 0.47 |
| ▸ | ALB | P02768 | 1/20 | 0.47 |
| ▸ | IL2 | P60568 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27650809 | 1.00 | SIGMAR1 (0.54) | SIGMAR1MMEACECPA1ACE2 | |
| SCHEMBL2888909 | 0.86 | MME (0.56) | MMEACECPA1ACE2CA2 | |
| SCHEMBL1060389 | 0.86 | MME (0.56) | MMEACECPA1ACE2CA2 | |
| SCHEMBL27699637 | 0.85 | MME (0.56) | SIGMAR1MMEACECPA1ACE2 | |
| SCHEMBL27699635 | 0.85 | MME (0.56) | SIGMAR1MMEACECPA1ACE2 | |
| SCHEMBL1097466 | 0.84 | MME (0.57) | MMEACECPA1ACE2CA2 | |
| SCHEMBL7889581 | 0.83 | MME (0.62) | MMEACECPA1ACE2CA2 | |
| SCHEMBL839945 | 0.83 | MME (0.62) | MMEACECPA1ACE2CA2 | |
| SCHEMBL18435514 | 0.83 | MME (0.62) | MMEACECPA1ACE2CA2 | |
| SCHEMBL11241144 | 0.83 | MME (0.56) | MMEACECPA1ACE2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964601-B2 | Agonist or antgonist and binders and inversion of agonist | PALATIN TECHNOLOGIES, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7807678-B2 | Peptidomimetics of biologically active metallopeptides | PALATIN TECHNOLOGIES, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7732451-B2 | Naphthalene-containing melanocortin receptor-specific small molecule | PALATIN TECHNOLOGIES, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-7718802-B2 | Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders | PALATIN TECHNOLOGIES, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7709484-B1 | Substituted melanocortin receptor-specific piperazine compounds | PALATIN TECHNOLOGIES, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-7655658-B2 | Use of in the treatment of melanocortin receptor-associated disorders such as in treatment of anorexia, as a weight gain aid, for treatment of obesity | PALATIN TECHNOLOGIES, INC. (US) | 2010-02-02 | — | — | US | disclosed |
| WO-2009144432-A1 | MC4-R AGONISTS FOR THE TREATMENT OF OBESITY | PALATIN TECHNOLOGIES, INC. (US) | 2009-12-03 | — | — | WO | disclosed |
| US-7601753-B2 | Pyrrolidine melanocortin-specific compounds | PALATIN TECHNOLOGIES, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090253713-A1 | Small Molecule Compositions for Sexual Dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2009-10-08 | — | — | US | disclosed |
| US-7550602-B1 | Small molecule compositions for sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20050124636-A1 | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds | PALATIN TECHNOLOGIES, INC. (US) | 2005-06-09 | — | — | US | disclosed |
| US-20050038230-A1 | Linear and cyclic melanocortin receptor-specific peptides | PALATIN TECHNOLOGIES, INC. (US) | 2005-02-17 | — | — | US | disclosed |
| WO-2004098602-A1 | MELANOCORTIN RECEPTOR-SPECIFIC COMPOUNDS | PALATIN TECHNOLOGIES, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| US-20040167201-A1 | Pyrrolidine melanocortin-specific compounds | PALATIN TECHNOLOGIES, INC. (US) | 2004-08-26 | — | — | US | disclosed |
| US-20040157264-A1 | Piperazine melanocortin-specific compounds | PALATIN TECHNOLOGIES, INC. (US) | 2004-08-12 | — | — | US | disclosed |
| EP-1441750-A2 | LINEAR AND CYCLIC MELANOCORTIN RECEPTOR-SPECIFIC PEPTIDES | Palatin Technologies, Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| EP-1425029-A1 | PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES | Palatin Technologies, Inc. (US) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003013571-A1 | PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES | PALATIN TECHNOLOGIES, INC. (US) | 2003-02-20 | — | — | WO | disclosed |
| WO-2003006620-A2 | LINEAR AND CYCLIC MELANOCORTIN RECEPTOR-SPECIFIC PEPTIDES | PALATIN TECHNOLOGIES, INC. (US) | 2003-01-23 | — | — | WO | disclosed |
| WO-2002064091-A2 | MELANOCORTIN METALLOPEPTIDES FOR TREATMENT OF SEXUAL DYSFUNCTION | PALATIN TECHNOLOGIES, INC. (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167201-A1 | Pyrrolidine melanocortin-specific compounds | MC3R, MC1R, MC5R | SIGMAR1 211/4885MME 548/4885ACE 2918/4885 |
| US-20040157264-A1 | Piperazine melanocortin-specific compounds | MC1R, MC5R, MC3R | SIGMAR1 75/4885MME 1310/4885ACE 4005/4885 |
| US-20090253713-A1 | Small Molecule Compositions for Sexual Dysfunction | PDE3B, PDE3A, PDE5A | SIGMAR1 480/4885MME 1838/4885ACE 2813/4885 |
| US-20050124636-A1 | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds | MC1R, MC5R, MC4R | SIGMAR1 842/4885MME 3870/4885ACE 3668/4885 |
| US-20050038230-A1 | Linear and cyclic melanocortin receptor-specific peptides | MC1R, MC3R, MC5R | SIGMAR1 535/4885MME 305/4885ACE 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.